Dipeptidyl peptidase IV/CD26 (DP IV) is a multifunctional serine protease cleaving off dipeptides from the N-terminus of peptides. The enzyme is expressed on the surface of epithelial and endothelial cells as a type II transmembrane protein. However, a soluble form of DP IV is also present in body fluids. Large scale expression of soluble human recombinant His(6)-37 -766 DP IV, using the methylotrophic yeast Pichia pastoris, yielded 1.7 mg DP IV protein per litre of fermentation supernatant. The characterisation of recombinant DP IV confirmed proper folding and glycosylation similar to DP IV purified from porcine kidney. Kinetic comparison of both proteins using short synthetic substrates and inhibitors revealed similar characteristics. However, interaction analysis of both proteins with the gastrointestinal hormone GLP-1 7 -36 resulted in significantly different binding constants for the human and the porcine enzyme (K d = 153.0 ± 17.0 µM and K d = 33.4 ± 2.2 µM, respectively). In contrast, the enzyme adenosine deaminase binds stronger to human than to porcine DP IV (K d = 2.15 ± 0.18 nM and K d = 7.38 ± 0.54 nM, respectively). Even though the sequence of porcine DP IV, amplified by RT-PCR, revealed 88% identity between both enzymes, the species-specific variations between amino acids 328 to 341 are likely to be responsible for the differences in ADA-binding.
deaminase, collagen, fibronectin, HIV coat protein gp120, plasminogen, HIV tat protein and the tyrosine phosphatase CD45. However, these protein interactions do not affect the proteolytic activity of the enzyme (Augustyns et al., 1999; De Meester et al., 1999; Gorrell et al., 2001) .
DP IV occurs as a type II membrane protein in almost all mammalian tissues, although also a soluble form of the enzyme has been found in body fluids (Vanhoof et al., 1992) . It is a product of limited proteolysis within the N-terminal tail of the protein rather than an alternative splicing variant (Ogata et al., 1989; Iwaki-Egawa et al., 1998) . DP IV is present on the surface of stimulated T cells, B cells and natural killer cells (Bühling et al., 1994) . Additionally, it is found in a variety of tissues on epithelial, endothelial and acinar cells. In this context, the designation 'CD26' refers to its localisation as a cell surface antigen of lymphocytes. Within the hematopoietic system, the T cell activation marker, CD26, plays a key role in T cell-mediated immune responses by modifying the activity of peptides involved in immune regulation (Morimoto et al., 1998) . DP IV has been implicated to be involved in cancer and in HIV infection by mediating cell adhesion processes independently of its catalytic activity (Kameoka et al., 1993; De Meester et al., 1994) . The proteolytic activity is characterised by removing N-terminal dipeptides from peptides containing proline or alanine residues at the penultimate position with intermediate formation of an acyl enzyme (Demuth et al., 1995) . Cytokines, chemokines, neuropeptides, and growth factors containing either a proline, alanine or serine residue at the N-terminal penultimate position are attacked by DP IV (Hoffmann et al., 1993; Oravecz et al., 1997; Reinhold et al., 1997; Pospisilik et al., 2002b) .
It has been confirmed in several type 2 diabetes animal models that inhibition of DP IV has a beneficial effect on blood glucose homeostasis (Deacon et al., 1998; Pederson et al., 1998; Pospisilik et al., 2002a,b) which is due to its key role in the inactivation of the incretins, glucagonlike peptide 1 (GLP-1 7 -36 ) and glucose-dependent insulinotropic peptide (GIP). These gastrointestinal hormones stimulate the glucose-dependent insulin secretion (Deacon et al., 1995; Mentlein, 1999) , inhibit glucagon re-
Introduction
Dipeptidyl peptidase IV/CD26 (DP IV, EC 3.4.14.5) is an extracellular protein with multiple physiological func-lease and gastric emptying, and enhance growth and differentiation of β-cells as well as insulin gene expression (Pederson et al., 1996; Marguet et al., 2000; Drucker, 2001) .
In search for a proper expression system we evaluated the methylotrophic yeast Pichia pastoris (P. pastoris) which has gained widespread attention as an expression system (Trimble et al., 1991; Sreekrishna et al., 1997) . It represents an alternative approach to previously published methods, in which DP IV was either expressed in insect cells, where in contrast to the yeast expression system, incorporation of selenomethionine to obtain the phase in crystallography leads to expensive production costs (Dobers et al., 2002; Larsson et al., 2002) , or the enzyme was expressed in mammalian cells with low production rates (Tanaka et al., 1992) .
Here we describe the cloning and expression of human recombinant soluble human DP IV [His(6)-37 -766 hDP IV] in human COS-7 cells and in the yeast, P. pastoris. The primary structure, biochemical and kinetic properties as well as substrate and ADA binding of recombinant DP IV were characterised in comparison to the enzyme purified from porcine kidney (pDP IV).
Results

Expression of Soluble hDP IV
DP IV is naturally expressed as a type II transmembrane protein with a small cytosolic tail (amino acids 1 -5) and a more extended transmembrane region (amino acids 6 -28). However, purification of DP IV from different sources revealed shortened (between ∆1 -28 and ∆1 -38 amino acids), soluble forms (Vanhoof et al., 1992; Fan et al., 1997; Iwaki-Egawa et al., 1998; Pederson et al., 1998) . Therefore, the cytosolic tail and the transmembrane domain located at the N-terminus were removed by amplifying the coding region between amino acid residues 37 and 766. Two mammalian expression constructs complemented by an N-terminal His 6 -tag were generated. One expression construct without a signal sequence (pAW3) should lead to a cytosolic expressed form of His(6)-37-766 hDP IV and the second construct (pAW9) was designed for secretion into the media. Transfection of COS-7 cells with pAW3 and transient expression revealed cytosolic expression of soluble His(6)-37-766 hDP IV as demonstrated by Western blot analysis. However, no DP IV-catalysed hydrolysis of the substrate Gly-Pro-pNA by the soluble fraction of the cells could be detected. No activity was found when expressing the enzyme in the cytosol suggesting that post-translational modifications of DP IV are necessary for correct folding or establishment of the catalytic activity. This confirms reports of impaired activity of full-length DP IV after deletion of the glycosylation sites (Fan et al., 1997) . Using the secretion construct (pAW9), proteolytically active DP IV was transiently secreted into the media, and the protein was detected by Western blot analysis (data not shown). However, we did not succeed in isolating stably transfected COS-7 cells expressing DP IV. Consequently, for large scale expression, a system had to be chosen which was capable of glycosylation similar to that in mammals and secretion into the media. The P. pastoris expression system can fulfil these requirements. Using the expression vector pPICZα C (Invitrogen, Groningen, Netherlands) for secretional expression, the encoding sequence of DP IV supplemented by an N-terminal His 6 -tag was cloned directly downstream of the α-factor secretion signal. After transfection of the P. pastoris strain X-33, 120 clones were analysed by small scale expression in shaking flasks for production of active DP IV. All clones tested were able to express proteolytically active DP IV as confirmed by Western-blot analysis using an anti-penta-His-tag antibody (Qiagen, Hilden, Germany) and activity measurements.
Fermentation and Purification of Soluble Human DP IV
Clone 36, displaying the highest activity, was used for cultivation in a 5 l fermenter. To obtain large cell masses, the fermentation was started with a 25 hour glycerolbatch phase followed by a 5 hour glycerol-fedbatch phase. Subsequently, DP IV expression was induced with methanol in a fed batch mode. Forty hours of fermentation under methanol induction yielded 15 U/l of active DP IV. After removing the yeast cells by centrifugation, the enzyme was purified from the supernatant by affinity chromatography on a Ni-NTA column. However, the eluted fraction still contained low amounts of impurities. Therefore, the fraction was concentrated by ultrafiltration and applied to a gel filtration column. Purification of recombinant His(6)-37-766 hDP IV from 2 l of supernatant yielded 3.4 mg recombinant His(6)-37-766 hDP IV (protein concentration was determined at OD 280 ) with a specific activity of 18 U/mg (U=units: turnover rate of 1 µM of Gly-Pro-AMC per minute). The purification yielded 32% activity of recombinant His(6)-37-766 hDP IV with a purification factor of 598. SDS-PAGE and silver staining revealed one broad protein band at 100 kDa without any visible impurity ( Figure 4B ).
Sequence Analysis of Porcine DP IV
Porcine kidney DP IV has been widely used to investigate biochemical and enzymatic properties of DP IV due to simple and effective purification, yielding high amounts of protein (see Materials and Methods). However, the complete primary sequence is still unknown. Hence, total RNA was isolated from porcine kidney and the ORF (open reading frame) was obtained by RT-PCR. Based on a published sequence at the 5'-end (Qvist et al., 1998) , a specific primer was designed. The second primer matched an internal sequence around the active site histidine, assuming sequence identity with human DP IV.
Thus, almost the complete ORF was amplified and sequenced. To obtain the missing 3'-end of the porcine DP IV cDNA ORF, 3'-RACE was performed, using a primer based on the obtained sequence information (primer E7). The final sequence contained an ORF with 2298 bp coding for 766 amino acids (Figure 1 ; GenBank accession number of the porcine DP IV sequence: AY198323). The amino acid sequence revealed 92.6% similarity and 88.4% identity to the human DP IV sequence. Seven glycosylation sites (underlined in Figure 2 ) are conserved Expression of DP IV/CD26 1555 between these two enzymes. However, a slight variation was observed in glycosylation, with a shift from Asn279 to Asn281 in hDP IV. The DP IV sequence differs in a predicted glycosylation site at Asn520 for hDP IV, whereas pDP IV revealed further putative sites at Asn179 and Asn393 as marked in Figure 2 . 
Characterisation of Human DP IV
Gel filtration analysis revealed a molecular mass of 187 kDA, indicating the existence of a His(6)-37-766 hDP IV dimer under native conditions ( Figure 3 ). The molecular mass of the monomeric subunits of recombinant His(6)-37-766 hDP IV and purified pDP IV were determined by MALDI-TOF mass spectrometry to be 103.6 kDA and 100.8 kDA, respectively. The mass peak of recombinant His(6)-37-766 hDP IV showed a broader mass distribution than that of pDP IV. A similar effect was also observed during isoelectric focusing ( Figure 4A ) where recombinant His(6)-37-766 hDP IV displayed a broader distribution of isoforms with pI-values of 5.47 to 6.26, compared with the enzyme purified from porcine kidney (pI: 5.57 to 6.16).
The kinetic parameters of DP IV-catalysed hydrolysis of short synthetic substrates by both enzymes (Table 1) did not differ significantly. Similarly, inhibition of recombinant His(6)-37-766 hDP IV by dipeptide analogue inhibitors results in an inhibition pattern almost identical to that of pDP IV (Table 1) . Only the K m and k cat values obtained for substrates containing proline in the P 1 -position are slightly lower in the case of the recombinant His(6)-37-766 hDP IV-catalysed hydrolysis. In contrast to the similar binding properties of low molecular mass effectors, analysis of binding properties of ADA (adenosine deaminase) and GLP-1 7 -36 revealed differences between the two DP IV's. Using plasmon resonance spectroscopy, molecular interactions of both enzymes with a natural DP IV-substrate, incretin GLP-1 7 -36 , was analysed. Binding of GLP-1 7 -36 to pDP IV was tighter than to recombinant His(6)-37-766 hDP IV (K d = 33.4 ± 2.2 µM and K d = 153.0 ± 17.0 µM, respectively). In contrast, binding of ADA to pDP IV was found to be 3.4 times weaker than to recombinant His(6)-37-766 hDP IV (K d values: 2.15 ± 0.18 nM and 7.38 ± 0.54 nM, respectively; see Figure 5 ).
Expression of DP IV/CD26 1557 (A) Proteins were subjected to Servalyte pre net gels (3 -10) and stained with Coomassie Brillant Blue R-250. Lane 1 and 2 correspond to isoelectric markers; lane 3 to porcine DP IV (IP: 5.57 -6.16); and lane 4 to human recombinant DP IV expressed and purified from P. pastoris (IP: 5.47 -6.26). (B) Lane 1 corresponds to molecular mass standards; lane 2 to recombinant His(6)-37-766 hDP IV applied to the gel after purification by Ni-NTA affinity chromatography and size exclusion chromatography. Proteins were visualised by silver staining. Human DP IV Porcine DP IV
Gly-Pro-AMC 41.8 ± 1.2 11.0 ± 0.3 260.0 ± 5.0 61.1 ± 1.7 23.2 ± 0.5 379.0 ± 8.0 Lys-Ala-AMC 262.4 ± 8.9 2.9 ± 0.1 11.4 ± 0.6 277.5 ± 9.1 4.0 ± 0.1 14.5 ± 0.3 Gly-Pro-pNA 67.4 ± 2.7 63.1 ± 2.1 937.0 ± 9.1 105.2 ± 3.9 46.5 ± 0.9 440.0 ± 7.2
Ile-Thia 102.8 ± 28.4 85.0 ± 6.6 Ile-Cyano-Pyrr 3.8 ± 0.2 3.9 ± 0.1 Ile-Thia: isoleucyl-thiazolidine; Ile-Cyano-Pyrr: isoleucyl-(2)-cyanopyrrolidine.
Discussion Expression of Soluble His(6)-37-766 hDP IV
In order to obtain an expression system for the production of proteolytically active DP IV, we investigated two different eukaryotic expression systems, human COS-7 cells and the yeast Pichia pastoris. Although COS-7 cells failed to produce recombinant DP IV for preparative purposes, we could demonstrate in this system that the secretional expression of an N-terminally truncated and His 6 -tagged protein displayed proteolytic activity, whereas cytosolic expression resulted in the synthesis of an inactive protein.
Thus, one can deduce that secretional expression is a prerequisite for post-translational modification necessary for correct folding and/or proteolytic activity of DP IV. In search for a eukaryotic expression system to provide significant amounts of DP IV, Dobers et al. (2002) explored the possibility of producing DP IV in insect cells. In contrast, to obtain cost effective high expression, we explored the eukaryotic P. pastoris expression system, which allows easy genetic manipulations and has the possibility of high scale fermentation as well as the expression of selenomethionine-containing proteins for crystallisation purposes. Expression in P. pastoris allows one to take advantage of a highly inducible promoter for protein expression along with the ability to use the classical and molecular genetic manipulation methods (Romanos et al., 1992) . Furthermore, the techniques can be elaborated to grow expression clones in large, high-density fermenter cultures (Cregg et al., 1993) . DP IV exists in a soluble form where the intracellular domain and the transmembrane anchor are proteolytically cleaved off without losing its binding properties and enzymatic activity (Ogata et al., 1989; Yaron et al., 1993; De Meester et al., 1999; Dobers et al., 2002) . The construction of such a truncated form of human DP IV was performed to obtain a soluble form of the enzyme. This was achieved by deleting the first 36 amino acids from the N-terminus and replacing them with a His 6 -tag to allow for affinity chromatography and Western blotting detection.
We could demonstrate that Pichia pastoris secretes soluble, active recombinant His(6)-37-766 hDP IV into the medium, thus providing further evidence that the intracellular domain and transmembrane anchor are not essential for folding and trafficking in yeast. In contrast to Dobers et al. (2002) , who produced a non-truncated DP IV in insects cells, we did not experience a loss of activity during purification of His(6)-37-766 hDP IV with an N-terminal His 6 -tag by affinity chromatography. Different constructs were also designed with the His 6 -tag attached at either the C-terminal or both C-and N-terminal sides or not at all, and all of them expressed a soluble, stable and active enzyme. Unlike the DP IV construct without a His 6 -tag, all tagged proteins were successfully purified by affinity chromatography and revealed no differences in activity (data not shown). Thus, one can conclude that the loss of activity observed by Dobers et al. (2002) may be caused by the membrane anchor which might have interfered with the column or other surfaces. The purification of His(6)-37-766 hDP IV expressed in P. pastoris resulted in 1.7 mg of homogenous DP IV per litre of fermentation supernatant. This is comparable to the 2 mg/l obtained by Dobers et al. (2002) from insect cell expression.
Structural Characterisation
In order to evaluate recombinant human DP IV, we compared it with purified porcine kidney DP IV with respect to biochemical, physical and kinetic properties. The amino acid sequences displayed 91.9% similarity and 87.5% identity. A comparison of both DP IV's from different species, which represent naturally occurring variants of the enzyme, can facilitate structural-functional relation studies and aid in deducing the importance of distinct amino acid exchanges. Native DP IV purified from porcine kidney, in contrast to the recombinant enzyme expressed in P. pastoris, might also display variations in their glycosylation. It has been shown that glycosylation with a high mannose-type is necessary for proper folding and activity of the enzyme (Loch et al., 1992) . This can also be provided by P. pastoris expression which is capable of glycosylation in a similar pattern, as observed in mammalian proteins (Cregg et al., 1993) . Nine and ten glycosylation sites were predicted for human and porcine DP IV, respectively. The monomeric molecular mass of human DP IV is predicted to be 88.0 kDA, however, 103.6 kDA was experimentally determined. This difference can be attributed to posttranslational modifications, mainly glycosylation, as described in the literature (Fukasawa et al., 1981; Kähne et al., 1996; Fan et al., 1997) . A higher molecular mass and a broader distribution of the isomers in isoelectric focusing suggests a higher and more heterogeneous glycosylation of the recombinant human compared to native porcine DP IV.
Recent publications of the crystal structure of recombinant human DP IV from insect cells and native porcine DP IV (Engel et al., 2003; Hiramatsu et al., 2003; Rasmussen et al., 2003) confirmed our findings of the more heterogeneous human DP IV. Interestingly, the glycosylation pattern showed that DP IV seems to be glycosylated only at distinct sites. In human DP IV, seven out of the nine glycosylation sites were modified and in porcine DP IV only five of the potential ten asparagines had sugar residues attached. Hence, these observations provide an explanation for the differences in the heterogenic patterns of the two DP IV's observed in isoelectric focusing experiments. Nevertheless, the variations in glycosylation were not found to influence the overall activity. Alignments of human, porcine, rat, and mouse DP IV revealed several highly conserved potential glycosylation sites at Asn85, Asn92, Asn150, Asn219, Asn229, Asn321 and Asn685 (amino acid numbering based on the human sequence). The high conformity indicates that these sites could play a crucial role in the multiple functions of the enzyme. The mouse sequence has an additional predicted glycosylation site at Asn343 while pDP IV is the only enzyme with a predicted site at position Asn393 and no site at Asn520 compared to the other three sequences. In addition, notable differences exist at position Asn281 (hDP IV), which is Asn279 in pDP IV and was found to be glycosylated, but is missing in both rodent sequences. Engel et al. (2003) postulated that glycosylation at Asn279 is necessary for the observed tetramerisation of pDP IV. Lambeir et al. (1997) described high molecular mass clusters for native human DP IV in gel filtration experiments. However, we did not observe such aggregation for human recombinant DP IV under the conditions used for gel filtration (Figure 3) . Furthermore, we noticed an exchange of Cys339 in the human to Ser339 in the porcine sequence. Consequently, the disulfide bridge at Cys339 was found in the human structure whereas it is not present in porcine DP IV, which suggests a minor role of this bond in the stabilisation of the overall protein structure.
Kinetic Characterisation
Characterisation of effectors and interaction partners of DP IV were carried out with recombinant His(6)-37-766 hDP IV and pDP IV. Our results confirmed earlier work (Jiang et al., 1997) where competitive inhibition of DP IV by isoleucyl-thiazolidine revealed a K i of 120.0 nM for human DP IV from plasma which corresponds well with our results (102.8 ± 28.4 nM). Jiang et al. (1997) obtained a K i value of 1.1 -22.0 nM for the inhibition of human DP IV using isoleucyl-(2)-cyanopyrrolidine, which is also in agreeExpression of DP IV/CD26 1559 Fig. 6 Superimposition of the Region around the Catalytic Active Site Serine 630 of Human DP IV (Orange) and Porcine DP IV (Green). Amino acids of the active centre were used for the comparison of both structures. For the calculation of the RMS (root mean square) value, the amino acids of the human DP IV were used as the target molecule. Subsequently, each atom (without hydrogen atoms) of the porcine DP IV was put on the corresponding atom of the target molecule and a good match was found (RMS value: 0.34 Å). This value is in the range of the X-ray determination accuracy. The catalytic triad is shown in red. ment with our results of 3.83 ± 0.20 nM. These results are supported by the fact that the active site is highly conserved, 97%, in both DP IV enzymes as shown in Figure 6 . Comparison of the X-ray structures of human DP IV and porcine DP IV by superimposing amino acids around the active centre demonstrate the high similarity in this region. Only an amino acid exchange at position 562 at the edge of the catalytic centre results in a minor variation in the orientation of the amino acid side chain. These facts substantiate porcine DP IV as a useful tool in studying kinetics with short substrates and inhibitors.
However, binding of a natural, 30 amino acid long substrate of DP IV, GLP-1 7 -36 , differed between both proteins, although human and porcine GLP-1 7 -36 sequences are identical. The sequence of the propeller region (residues 55 -497), where the substrate could possibly enter (Engel et al., 2003; Hiramatsu et al., 2003; Rasmussen et al., 2003) , features a lower identity of 85% between the human and porcine DP IV. These findings support speculations that secondary interactions with substrates distant from the active centre might be responsible for specific variations in the affinity of larger substrates. So far, no 3D-structure has been published presenting DP IV co-crystallised with a natural substrate, which would allow the identification of essential amino acids responsible for secondary interactions with longer peptide substrates and perhaps help explaining the observed differences in binding of GLP-1 by the enzymes.
There are small differences in the N-terminal portion of DP IV purified from porcine kidney and the recombinant human enzyme. Our recently published crystal structure confirms a flexible N-terminus distant from the catalytic side, the ADA binding site and the proposed substrate entrances (Engel et al., 2003) . Thus, no influence on binding and activity by shortening the N-terminus are expected. Moreover, in the normal physiological environment the N-terminus of DP IV is localised intracellularly, separated by a 22 amino acid membrane anchoring region and the membrane itself from the extracellular part of the protein. With exception of the His 6 -tag the length of the N-termini of the porcine and the recombinant human DP IV differ only by two amino acids. The porcine DP IV starts at Ser39 whereas the human starts at Ala37. An influence of the His 6 -tag on hydrolysis of low molecular weight substrates could be excluded (see above) indicating no significant influence of the His 6 -tag on the overall structure of the enzyme. DP IV interaction with ADA has been extensively studied and differences between various species were found. Interaction between these two proteins has been described for rabbit, bovine and human (Dong et al., 1997) ; however, no DP IV-ADA binding was observed for rat and mouse DP IV (De Meester et al., 1996) . We measured stronger binding of ADA to human than to porcine DP IV. The ADA binding site of human DP IV was previously verified in several studies (De Meester et al., 1994; Dong et al., 1997; Abbott et al., 1999) . Amino acids important for ADA binding were identified to be at positions 294, 340 -343, 440 and 441 (Abbott et al., 1999) . The porcine sequence shows amino acid exchanges in position 338 -340, overlapping with this ADA binding region. This leads to a change in the hydrophobicity of the area which is postulated to be important for ADA binding. Furthermore, the human enzyme displays a cysteine bridge with Cys339, stabilising the ADA binding region, which is not present in porcine DP IV.
In summary, we have demonstrated that secretional expression of His 6 -tagged human DP IV is possible in P. pastoris. This allows fermentation and rapid purification of large quantities of active enzyme comparable to the high yield of a porcine kidney DP IV preparation. Small effectors bind in comparable fashion to both enzymes. In contrast, larger substrates, such as GLP-1 7 -36 , which displayed differences in their affinity, indicate secondary interactions with less conserved regions of the enzyme. Binding differences were also found for the external surface binding protein ADA, which could be explained by amino acid exchanges near the binding site. Protein expression in P. pastoris is a useful tool for the production of high quantities of DP IV as well as rapid manipulation on the enzyme for further structure-activity relation studies.
Materials and Methods
Sequence Analysis of Porcine DP IV
To obtain the sequence of porcine DP IV, total RNA was extracted from porcine kidney using TRIzol ® reagent following the protocol from Gibco-BRL (Invitrogen, Groningen, Netherlands). cDNA synthesis was carried out using the ThermoScript™ RT-PCR system (Invitrogen) using random hexamer primers following the protocol from Gibco-BRL (Invitrogen). Amplification of pDP IV sections (a-c) was performed using Platinum Taq High Fidelity (Invitrogen): (a) pDP IV 1 -908 (primer E1/E2); (b) pDP IV 738 -1505 (primer E3/E4); (c) pDP IV 1375 -2051 (primer E5/E6) ( Table 2) . cDNA synthesis and sequencing of base pairs 2052 -2470 were accomplished by the 3'RACE (Rapid Amplification of cDNA Ends) system (Invitrogen). Amplification of the target cDNA was carried out with primer E7 and AUAP (5'-GGC-CACGCGTCGACTAGTAC-3') and amplification of the section 1879 -2298 with primers E7 and E8.
Strains and Plasmids
P. pastoris strain X-33 and the vectors pPICZα C and pcDNA-3.1 were purchased from Invitrogen. E. coli XL-10 cells were provided by Stratagene (La Jolla, USA). Dipeptidyl peptidase IV cDNA was a generous gift of Dr. Fleischer, Hamburg, Germany.
Plasmid Construction
The protein sequence of soluble hDP IV, ∆1 -36 hDP IV, was amplified by PCR using primers containing an EcoRI (D1) or a XhoI (D2) restriction enzyme recognition site. The product obtained was cloned into the pPCR Script Cam vector (Stratagene). The EcoRI and XhoI restriction sites were used to ligate the fragment into the mammalian expression vector, pcDNA-3.1 (Invitrogen). Two different kinds of expression constructs, a cytosolic construct (designated pAW3) and a secretion construct (designated pAW9) were generated by adding a Kozac sequence and a His 6 -tag (HHHHHH) (C1 and C2, Table 2 ) or a Kozac sequence, a signal sequence and a His 6 -tag at the 5'-end of the DP IV ORF by cassette mutagenesis (C3-C6, Table 2 ). To generate a Pichia pastoris expression construct, the whole hDP IV coding region, N-terminally truncated (∆1 -36) and fused to the His 6 -tag, was inserted in a pcDNA-3.1 vector. The sequence could be amplified with the use of primers D3 and D4 which contain the restriction sites for KpnI and BspD1, respectively, and then cloned into pPCR-Script Cam. Using the introduced restriction sites, the fragment was ligated into the P. pastoris vector, pPICZα C. Constructs containing a His 6 -tag at the 3'-end, double His 6 -tagged at the 3'-and the 5'-end and a construct containing no His 6 -tag were generated by cassette mutagenesis (C3-C6, Table 2 ). The P. pastoris expression constructs were transformed following the protocols from Invitrogen.
Transfection of COS-7 cells (ACC 60, provided by DSMZ, Braunschweig, Germany) by pAW3 [pcDNA3.1(+)], was carried out using LipofectAMINE™ 2000 from Invitrogen, while pAW9 was transfected with PolyFect from Qiagen (Hilden, Germany). Stable transfectants were selected in medium containing 400 µg/ml G418 (Duchefa, Haarlem, Netherlands).
Small-Scale Expression Studies
Media for fermentation and shaking flask culture were prepared as described in the Invitrogen Pichia pastoris fermentation process guidelines using chemicals purchased from Sigma. Single colonies were grown overnight in 2 ml BMGY (buffered minimal glycerol medium) at 28°C and 250 rpm on a shaking platform. Cells were pelleted by centrifugation at 1000 g for 5 minutes at room temperature in a Beckmann JS-4.3 swing out rotor (Palo Alto, USA) and resuspended in 2 ml BMMY (buffered minimal methanol medium). Induction of gene expression was initiated with a methanol concentration of 0.5% (v/v) . DP IV activity in the expression medium was assayed after 48 hours. Clones displaying highest activity were monitored further in a shaking flask culture (15 ml BMGY or 15 ml BMMY) with respect to their growth rate, phenotype (Mut S , slow utilisation of methanol; or Mut + , normal methanol utilisation rate) and expression rate. A 2 l fermentation was inoculated with 200 ml of a preculture following the Invitrogen Pichia pastoris fermentation process guidelines. The fermentation procedure was carried out in a 5 l Biostat-B reactor (B.Braun, Melsungen, Germany).
Purification of DP IV
Fermentation medium was centrifuged at 40 000 g for 20 minutes at 4°C in a Beckmann JLA 16.250 rotor (Palo Alto, USA) to pellet the yeast cells. The supernatant was filtered to remove any residual solids and concentrated, using a tangential flow filtration system from Satorius, Göttingen, Germany (cut-off: 30 kDa). Affinity chromatography was carried out at 4°C with a Ni-NTA sepharose column (Qiagen). The column was pre-equilibrated with 50 mM NaH 2 PO 4 buffer, pH 7.6, 300 mM NaCl, 5 mM imidazole. The enzyme was eluted with increasing imidazole concentrations. The fractions with the highest DP IV-content were pooled and concentrated to 0.5 ml using an Amicon ultrafiltration cell (cut-off: 10 kDa). This volume was applied to a Superdex 200 gel filtration column (Amersham, Uppsala, Sweden). The column was equilibrated with 50 mM NaH 2 PO 4 buffer, pH 7.6, containing 300 mM NaCl with a flow rate of 0.25 ml/min. His(6)-37-766 hDP IV containing fractions were concentrated to 1 ml as described above.
pDP IV was purified from the cortex of pig kidney. The procedures included tissue homogenisation, membrane autolysis, differential centrifugation, ammonium sulphate precipitation, onestep preparative size exclusion chromatography, and one-step ion exchange chromatography according to modified methods described in Fischer et al. (1983) and Demuth et al. (1995) . Final purification of the naturally glycosylated protein to homogeneity was achieved by preparative isoelectric focusing using the Rotofor system (Bio-Rad, Hertfordshire, UK). Starting with 2 kg of tissue, the procedure yielded almost 60 mg of total protein, purified by a factor of approximately 280.
DP IV Activity Measurements
DP IV-activity was determined according to methods described earlier in Fischer et al. (1983) and Demuth et al. (1989 Demuth et al. ( , 1995 . The Expression of DP IV/CD26 1561 D1  5´-CAT GAA TTC AAA ACT TAC ACT CTA ACT G-3D  2  5´-GAC TCG AGC TAA GGT AAA GAG AAA CAT TG-3Ć  1  5´-GAT CCG CCA GCC ATG GTA CAT CAT CAT CAT CAT CAT G-3´  C2  5´-AAT TCA TGA TGA TGA TGA TGA TGT ACC ATG GCT GGC G-3Ć  3  5´-GAT CCA CCA TGG AGA CAG ACACAC TCC TGC TAT GGG TAC TGC TGC TC-3Ć  4  5´-AAC CCA GAG CAG CAG TAC CCA TAG CAG GAG TGT GTC TGT CTC CAT GGT G-3Ć  5  5´-TGG GTT CCA GGT TCC ACC GGT GAC GCG CAT CAT CAT CAT CAT CAT G-3Ć  6  5´-AAT TCA TGA TGA TGA TGA TGA TGC GCG TCA CCG GTG GAA CCT GG-3D  3  5´-TCATCGATGCATCATCATCATCATCAT-3´  D4 5´-TAGGTACCGCTAAGGTAAAGAGAAAC-3´ E1 5'-ATGAAGACACCGTGGAAGG-3' E2 5'-ACGCCACACAAGTAGTGATC-3' E3 5'-GCAGTACCCAAAGACTGTGC-3' E4 5'-TTATCCAAAGCTGAATGGTC-3' E5 5'-GCATCATTTAGTAACAAGGC-3' E6 5'-CTGTAATAGTCAAGGTTGTC-3' E7 5'-TGGGGCTGGGCATATGGAGG-3' E8 5'-GACTCGAGCTAAGGTAAAGAGAAACATTG-5'
The generated restriction sides EcoRI and XhoI are underlined. All primers were purchased from metabion (Munich, Germany).
kinetic experiments were conducted at 30°C in 40 mM HEPES buffer, pH 7.6. Fluorimetric measurements of the cleavage of AMC (7-amido-4-methylcoumarin)-containing substrates were carried out on a thermostated fluorimeter (SFM25, Kontron, Munich, Germany), while liberation of AMC by the enzyme was monitored at 380/460 nm (excitation/emission wavelength). Spectrophotometric measurements of DP IV-catalysed hydrolysis of substrates containing pNA as the chromogenic leaving group were carried out using an UV/vis spectrophotometer (Lambda 20, Perkin Elmer, Überlingen, Germany). Kinetic constants (k cat and K m ) were determined from initial rate measurements, using substrate concentrations in the range of 0.2 -10 times the K m value. The kinetic parameters were calculated with non-linear regression analysis. Substrates were kindly provided by Dr. S. Manhart (Department of Peptide Chemistry, probiodrug AG).
Further Methods
Proteins were analysed by SDS-PAGE according to Laemmli (1970) using 12% (w/v) separating and 3% (w/v) stacking gel. Gels were stained using Coomassie Brilliant Blue R-250 (Roth, Karlsruhe, Germany) or silver stained according to Blum et al. (1987) . The isoelectric point of DP IV was determined using Servalyte pre net gels (pH gradient from pH 3 to 10) and standards from Serva (Heidelberg, Germany) using a Multiphor II electrophoresis system (Pharmacia, Erlangen, Germany).
Mass spectrometry was performed with a LD-TOF system G2025 (Hewlett Packard, Walbronn, Germany). Samples were desalted by dialysis against water before being applied to the matrix. The samples were mixed with the DHAP/DAHC-matrix, dissolved in 50% (v/v) acetonitrile and crystallised under vacuum. Calibration of the mass spectrometer was carried out using bovine serum albumin as standard.
The native molecular mass was determined using a Superdex 200 HiLoad 26/60 column (Pharmacia, Uppsala, Sweden) applying a flow rate of 0.5 ml/min with 10 mM sodium phosphate buffer. A gel filtration molecular mass standard purchased from Bio-Rad was used.
A BIAcore 3000 instrument (BIAcore AB, Freiburg, Germany) with concomitant BIAevaluation software (version 3.01) and a CM5 Research Grade Sensor Chip (carboxymethyldextran matrix) was used to determine the affinity of DP IV to adenosine deaminase and GLP-1. DP IV was coupled covalently to the sensor chip surface using amine coupling chemistry. Binding assays were performed using a HBS-N buffer, pH 7.4 (BIAcore) at a constant flow rate of 20 µl/min. Data analysis to determine the dissociation constants for protein-protein interactions was carried out with BIAevaluation v3.01 software.
